This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, S. Articles by Leppla, S. H. Search for Related Content PubMed PubMed Citation Articles by Liu, S. Articles by Leppla, S. H.

Tumor Cell-selective Cytotoxicity of Matrix Metalloproteinase-activated Anthrax Toxin

Oral Infection and Immunity Branch [S. L., S. H. L.] and Matrix Metalloproteinase Unit [S. N-A., H. B-H.], National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892

Matrix metalloproteinases (MMPs) are overexpressed in a variety of tumor tissues and cell lines, and their expression is highly correlated to tumor invasion and metastasis. To exploit these characteristics in the design of tumor cell-selective cytotoxins, we constructed two mutated anthrax toxin protective antigen (PA) proteins in which the furin protease cleavage site is replaced by sequences selectively cleaved by MMPs. These MMP-targeted PA proteins were activated rapidly and selectively on the surface of MMP-overexpressing tumor cells. The activated PA proteins caused internalization of a recombinant cytotoxin, FP59, consisting of anthrax toxin lethal factor residues 1–254 fused to the ADP-ribosylation domain of Pseudomonas exotoxin A. The toxicity of the mutated PA proteins for MMP-overexpressing cells was blocked by hydroxamate inhibitors of MMPs, including BB94, and by a tissue inhibitor of matrix metalloproteinases (TIMP-2). The mutated PA proteins killed MMP-overexpressing tumor cells while sparing nontumorigenic normal cells when these were grown together in a coculture model, indicating that PA activation occurred on the tumor cell surface and not in the supernatant. This method of achieving cell-type specificity is conceptually distinct from, and potentially synergistic with, the more common strategy of retargeting a protein toxin by fusion to a growth factor, cytokine, or antibody.

This article has been cited by other articles:

				R. W. Alfano, S. H. Leppla, S. Liu, T. H. Bugge, M. Herlyn, K. S. Smalley, J. L. Bromberg-White, N. S. Duesbery, and A. E. Frankel Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells Mol. Cancer Ther., May 1, 2008; 7(5): 1218 - 1226. [Abstract] [Full Text] [PDF]

				S. Liu, H. Wang, B. M. Currie, A. Molinolo, H. J. Leung, M. Moayeri, J. R. Basile, R. W. Alfano, J. S. Gutkind, A. E. Frankel, et al. Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature J. Biol. Chem., January 4, 2008; 283(1): 529 - 540. [Abstract] [Full Text] [PDF]

				M. Moayeri, J. F. Wiggins, and S. H. Leppla Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and Rats Infect. Immun., November 1, 2007; 75(11): 5175 - 5184. [Abstract] [Full Text] [PDF]

				K.-H. Chen, S. Liu, L. A. Bankston, R. C. Liddington, and S. H. Leppla Selection of Anthrax Toxin Protective Antigen Variants That Discriminate between the Cellular Receptors TEM8 and CMG2 and Achieve Targeting of Tumor Cells J. Biol. Chem., March 30, 2007; 282(13): 9834 - 9845. [Abstract] [Full Text] [PDF]

				C. Springfeld, V. von Messling, M. Frenzke, G. Ungerechts, C. J. Buchholz, and R. Cattaneo Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res., August 1, 2006; 66(15): 7694 - 7700. [Abstract] [Full Text] [PDF]

				V. V. Artym, Y. Zhang, F. Seillier-Moiseiwitsch, K. M. Yamada, and S. C. Mueller Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res., March 15, 2006; 66(6): 3034 - 3043. [Abstract] [Full Text] [PDF]

				S. Vessillier, G. Adams, and Y. Chernajovsky Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3 Protein Eng. Des. Sel., December 1, 2004; 17(12): 829 - 835. [Abstract] [Full Text] [PDF]

				S. Liu and S. H. Leppla Cell Surface Tumor Endothelium Marker 8 Cytoplasmic Tail-independent Anthrax Toxin Binding, Proteolytic Processing, Oligomer Formation, and Internalization J. Biol. Chem., February 7, 2003; 278(7): 5227 - 5234. [Abstract] [Full Text] [PDF]

				S. Liu, H. Aaronson, D. J. Mitola, S. H. Leppla, and T. H. Bugge Potent antitumor activity of a urokinase-activated engineered anthrax toxin PNAS, January 21, 2003; 100(2): 657 - 662. [Abstract] [Full Text] [PDF]

				A. E. Frankel Increased Sophistication of Immunotoxins Clin. Cancer Res., April 1, 2002; 8(4): 942 - 944. [Full Text] [PDF]

				S. Liu, T. H. Bugge, and S. H. Leppla Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin J. Biol. Chem., May 18, 2001; 276(21): 17976 - 17984. [Abstract] [Full Text] [PDF]